FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (NDA) for sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS).

MANILA, Philippines — The Mall of Asia Arena (MOA) has installed a brand new centerhung, an upgrade on the original jumbotron that hung at the venue since 2012. The installation of the "The Cube ...

In the Philippines, few developments reflect this shift more clearly than the Mall of Asia (MOA) complex in Pasay City. Across a single district, MOA brings together a rare convergence ...

BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental ...

BOSTON — Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

For the first time, ancient DNA from droppings left by New Zealand’s flightless moa identifies actual species of fungi the doomed birds ate. The snacks, including purple lumps of a trufflelike ...

In their study published in the journal Biology Letters, the group conducted a DNA analysis of fossilized moa dung. As the global climate has warmed, scientists have continued to learn more about ...

Moa Technology, which counts Lansdowne Partners and OSE among its backers, has kicked off talks with investors about raising £32m to fund a path to regulatory approval, Sky News learns. An Oxford ...

On Monday, BYU linebacker Aisea Moa entered the NCAA Transfer Portal. He will have two years of eligibility remaining at his next school. Moa has been in the program at BYU since 2022. After ...

Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. (Travere) and currently in phase III clinical trials in ...